<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01276210</url>
  </required_header>
  <id_info>
    <org_study_id>VICC RAD1060</org_study_id>
    <secondary_id>NCI-2010-02407</secondary_id>
    <nct_id>NCT01276210</nct_id>
  </id_info>
  <brief_title>Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases</brief_title>
  <official_title>A Phase I Trial of Sorafenib and Stereotactic Radiosurgery for Patients With 1-4 Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth or by blocking blood flow to the tumor. Stereotactic&#xD;
      radiosurgery (SRS) may be able to send x-rays directly to the tumor and cause less damage to&#xD;
      normal tissue. Giving sorafenib tosylate together with SRS may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and the best dose of sorafenib&#xD;
      tosylate when given together with SRS in treating patients with brain metastases&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety, tolerability and maximum tolerated dose (MTD) of sorafenib, when&#xD;
      administered in combination with SRS to patients with 1-4 metastatic brain tumors.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the six-month intra-cranial progression-free survival (PFS) of sorafenib when&#xD;
      administered in combination with SRS to patients with 1-4 metastatic brain tumors. PFS is&#xD;
      defined as the time to intra-cranial tumor progression or death.&#xD;
&#xD;
      II. To assess the six-month overall survival (OS) of sorafenib when administered in&#xD;
      combination with SRS to patients with 1-4 metastatic brain tumors.&#xD;
&#xD;
      III. To compare results to patients who are treated with SRS alone (concurrent controls).&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of sorafenib tosylate.&#xD;
&#xD;
      Patients receive oral (PO) sorafenib tosylate once daily and undergo SRS 5-7 days later.&#xD;
      Treatment with sorafenib continues for 2 weeks after SRS in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 8, 26, and 52 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD) of combining sorafenib with SRS</measure>
    <time_frame>At 1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra-cranial progression-free survival (PFS)</measure>
    <time_frame>At 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS) in study patient population</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Tumors Metastatic to Brain</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>BAY 43-9006</other_name>
    <other_name>BAY 43-9006 Tosylate Salt</other_name>
    <other_name>BAY 54-9085</other_name>
    <other_name>Nexavar</other_name>
    <other_name>SFN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic radiosurgery</intervention_name>
    <description>Undergo stereotactic radiosurgery</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed cancer with 1-4 brain metastases (except lymphoma or small&#xD;
             cell histologies)&#xD;
&#xD;
          -  ECOG PS 0 or 1&#xD;
&#xD;
          -  Patients are candidates for stereotactic radiosurgery as determined by the treating&#xD;
             radiation oncologist. Intra-cranial tumors must measure 4cm or less in greatest&#xD;
             dimension. Patients may have received prior neurosurgical resection(s) of&#xD;
             intra-cranial metastases if their operation(s) was (were) completed at least 6 months&#xD;
             prior to study enrollment. Patients may have had prior whole brain radiation therapy&#xD;
             (WBRT) if it was completed at least 6 months prior to study enrollment.&#xD;
&#xD;
          -  Age â‰¥ 18 years and willing and able to sign a written informed consent; a signed&#xD;
             informed consent must be obtained prior to any study specific procedures&#xD;
&#xD;
          -  INR &lt; 1.5 or a PT/PTT within normal limits; patients receiving anti-coagulation&#xD;
             treatment with an agent such as warfarin or heparin may be allowed to participate; for&#xD;
             patients on warfarin, the INR should be measured prior to initiation of sorafenib and&#xD;
             monitored at least weekly (INR must be therapeutic in the range of 2-3)&#xD;
&#xD;
        Subjects must receive 1st dose of sorafenib 5-7 days prior to administration of&#xD;
        Stereotactic Radiosurgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Congestive heart failure &gt; class II NYHA; patients must not have unstable angina&#xD;
             (anginal symptoms at rest) or new onset angina (began within the last 3 months) or&#xD;
             myocardial infarction within the past 6 months&#xD;
&#xD;
          -  Unable to undergo brain MRI&#xD;
&#xD;
          -  CNS metastases from lymphoma or small cell lung cancer&#xD;
&#xD;
          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy&#xD;
&#xD;
          -  Uncontrolled hypertension defined as systolic blood pressure &gt; 140mm Hg or diastolic&#xD;
             pressure &gt; 90 mm Hg, despite optimal medical management&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C&#xD;
&#xD;
          -  Active clinically serious infection &gt; CTCAE v 4.0 Grade 2&#xD;
&#xD;
          -  Thrombolic or embolic events such as a cerebrovascular accident including transient&#xD;
             ischemic attacks within the past 6 months&#xD;
&#xD;
          -  Pulmonary hemorrhage/bleeding event &gt;= CTCAE v 3.0 Grade 2 within 4 weeks of first&#xD;
             dose of study drug&#xD;
&#xD;
          -  Any other hemorrhage/bleeding event &gt;= CTCAE v 3.0 Grade 3 within 4 weeks of first&#xD;
             dose of study drug&#xD;
&#xD;
          -  Serious non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Any drug that results in hepatic enzyme induction such as anti-convulsants (dilantin,&#xD;
             depakote, tegretol, phenobarbital); keppra is allowed&#xD;
&#xD;
          -  Evidence or history of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Any pulmonary hemorrhage CTCAE v 4.0 Grade 2 or higher within 4 weeks of first study&#xD;
             drug&#xD;
&#xD;
          -  Any other bleeding or hemorrhage CTCAE v 4.0 Grade 3 or higher within 4 weeks of first&#xD;
             drug&#xD;
&#xD;
          -  Major surgery, open biopsy or significant traumatic injury within 4 weeks of first&#xD;
             study drug&#xD;
&#xD;
          -  Use of St. John's Wort or rifampin (rifampicin) within the last 8 weeks&#xD;
&#xD;
          -  Known or suspected allergy to sorafenib&#xD;
&#xD;
          -  Any condition that impairs patient's ability to swallow whole pills&#xD;
&#xD;
          -  Concurrent investigational drugs&#xD;
&#xD;
          -  Concurrent steroids are allowed if Dexamethasone dose is =&lt; 16mg daily; if feasible,&#xD;
             steroids should be weaned off once sorafenib has been initiated&#xD;
&#xD;
          -  Prior therapy with sorafenib or other tyrosine kinase inhibitors within the last 12&#xD;
             months; patients are allowed to have been on prior bevacizumab therapy as long as it&#xD;
             was stopped at least 6-8 weeks prior to enrolling on this trial&#xD;
&#xD;
          -  Any malabsorption problem&#xD;
&#xD;
          -  Hemoglobin =&lt; 9.0 g/dl&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) =&lt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count =&lt; 100,000/mm^3&#xD;
&#xD;
          -  Total bilirubin &gt;= 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST &gt;= 2.5 times the ULN ( =&lt; 5 x ULN for patients with liver involvement)&#xD;
&#xD;
          -  Creatinine &gt;= 1.5 times ULN&#xD;
&#xD;
          -  Women of childbearing potential with a positive serum pregnancy test performed within&#xD;
             7 days prior to the start of treatment; women and men of childbearing potential that&#xD;
             do not agree to use adequate contraception (barrier method of birth control) prior to&#xD;
             study entry and for the duration of study participation; men who do not agree to use&#xD;
             adequate birth control for at least three months after the last administration of&#xD;
             sorafenib&#xD;
&#xD;
          -  All toxicities from prior therapies must have resolved to CTCAE v3.0 Grade I or better&#xD;
             by the time of study enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anuradha Chakravarthy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vicc.org/ct/</url>
    <description>Vanderbilt-Ingram Cancer Center, Find a Clinical Trial</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>January 11, 2011</study_first_submitted>
  <study_first_submitted_qc>January 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2011</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>A Bapsi Chakravarthy, MD</investigator_full_name>
    <investigator_title>Associate Professor; Radiation Oncologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

